Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — Q3 2023 Earnings Presentation
15 slides from Laboratorio Reig Jofre's earnings presentation, 2023
Slide 1: 3Q Results 3rd Quarter 2023
REIG [QJ JOFRE TRADITION OF |NNOVATION 3Q RESULTS 3rd Quarter 2023
Slide 2: Table of Contents
TABLE OF CONTENTS 01 EARNINGS 3Q 2023 02 INCOME STATEMENT AND BALANCE 03 2023 PERSPECTIVES 04 RJF SHARE TRENDS
Slide 3: 3Q 2023 Results
(3) Nn = —! =) Nn Lu [a
Slide 4: Earnings 3rd Quarter 2023
EARNINGS 3rd QUARTER 2023 REIG JOFRE increased 22% in revenue and 24% in EBITDA in the closing of 2023 + 22% SALES The sales amount accumulated by September 2023 reaches 237 million euros, 22% above the same period of 2022. The medicinal products division, Speciality Pharmacare, leads this growth,
Slide 5: Income by Business Unit
INCOME BY BUSINESS UNIT PHARMACEUTICAL SPECIALITY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC Injectable / Freeze-dried products Dermatology Energy Stress and sleep 104,4 56,8 Weight control 76,0 Beauty 44 % Millions of€ 32% Millions of€ 24 % Millions of€ +19% +34% +11
Slide 6: Sales by Geographical Area
SALES BY GEOGRAPHICAL AREA Rest of Rest of SPAIN EUROPE WORLD 45% 43% 12% €106.7 M €101.5 M €29.1 M Spain Eupean 45% Union 36% + 22% + 14% + 51% The Spanish market continues to grow above 20% from the 12% it reached in 2022. The injectable products area is growing significantly due to the greater
Slide 7: Income Statement and Balance
INCOME STATEMENT AND BALANCE 02
Slide 8: Income Statement 3Q 2023
Trends 2023/2022 INCOME STATEMENT The 22% growth in Sales is achieved with a gross margin of 58%, at the closing levels of the previous year, despite the increases in 3Q 2023 material costs, thanks to a more favourable product mix. The activation level of R&D (work carried out for fixed assets)
Slide 9: Balance 3Q 2023 and Investment
BALANCE 7,0 3Q 2023 INVESTMENT 3Q23 thousand euros 30/09/2023 30/09/2022 Millions of € ASSETS Goodwill 28.775 29.485 Other intangible assets 65.166 73.196 R&D ACTIVATION Property, plant and equipment 88.679 91.549 Investments in equity-accounted investees Non-current financial assets measured at fai
Slide 10: Balance 3Q 2023 Net Financial Debt
BALANCE 3Q 2023 NET FINANCIAL DEBT Debt|EBITDA thousand euros 30/09/2023 30/09/2022 3Q23 59.5 TOTAL EQUITY 202.272 191.107 closing closing Millions of € 3Q23 1.7 Capital grants 3.467 3.916 Provisions 0 201 Financial liabilities with credit institutions Lease liabilities 16.885 9.551 28.565 13.176 cl
Slide 11: Perspectives 2023
PERSPECTIVES 2023 03
Slide 12: 2023 Perspectives
REIG JOFRE experienced a sales growth of 22% at the end of September, and an increase in EBITDA of 24%. Investments in recent years allowed this growth, which we hope can be maintained by the end of the year. REIG JOFRE maintained a growth of more than 20% in sales and results in the third quarter,
Slide 13: Progress of RJF Share YTD Jan. 2023 – Sep. 2023
PROGRESS OF RJF SHARE YTD Jan. 2023 – Sep. 2023 RJF (ISIN ES0165359029) Price Maximum Minimum +12% Market 2,45€ 2,82€ 2,29 € capitalisation 29/09/23 €195 M Price Volume Cash 2,59 € 8,629 €22.3 K 29September2023 Weighted mean Daily mean Daily mean SHAREHOLDERS REIG JOFRE INVESTMENTS SL DAILY MEAN VOL
Slide 14: Links and Additional Information
LINKS AND ADDITIONAL INFORMATION LAST NEWS WEBCAST DE RESULTADOS SUBSCRIPTION CENTRE www.reigjofre.com/en/news http://www.reigjofre.com/en/investors/webcasts https://reigjofre.com/en/news/subscription-center/
Slide 15: Thank you
3Q Thank you Av. de les Flors 08970 Sant Joan Despí Barcelona, Spain Tel: +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com